Within the cystic fibrosis therapeutics market, oral therapies held a 66.93% share in 2025, making this the leading route of administration segment. Its leadership is maintained through the central role of oral formulations in long-term disease management, where routine use, established prescribing familiarity, and easier administration support consistent patient adherence. In practical treatment settings, oral therapies fit more smoothly into daily care regimens than device-dependent alternatives, which helps preserve their dominant share across a broad treatment population in the cystic fibrosis therapeutics market.

Inhaled therapies are emerging as the fastest-growing route of administration in the cystic fibrosis therapeutics market as care increasingly emphasizes targeted drug delivery directly to the lungs, where the disease burden is most pronounced. This segment is gaining momentum because inhaled administration aligns closely with the respiratory nature of cystic fibrosis and supports treatment approaches designed to improve local therapeutic effect while fitting into evolving pulmonary care protocols. Compared with oral alternatives, inhaled therapies are benefiting from stronger demand for route-specific intervention in airway management, which is accelerating their uptake.

Distribution Channel Segment Analysis: Hospital Pharmacies (Largest Segment) vs Online Pharmacies (Fastest-Growing Segment)

Hospital pharmacies accounted for a 56.18% share in 2025 within the cystic fibrosis therapeutics market, establishing them as the largest distribution channel segment. Their leading position reflects the specialized and closely monitored nature of cystic fibrosis treatment, where patients often rely on hospital-based care pathways for prescription access, therapy management, and coordination with multidisciplinary clinical teams. This structure supports a strong and sustained share for hospital pharmacies in the cystic fibrosis therapeutics market, particularly for therapies that require careful oversight and continuity of supply.

Online pharmacies represent the fastest-growing distribution channel in the cystic fibrosis therapeutics market as patients and caregivers increasingly value more convenient access to recurring medications outside traditional dispensing settings. Growth in this segment is being driven by the practical advantage of refill efficiency and home-based delivery, which is especially relevant for chronic treatment schedules that demand ongoing access. Relative to hospital pharmacies, online pharmacies are seeing wider adoption where digital ordering and remote fulfillment better match evolving patient expectations around convenience and continuity.